I.V. NEYPHELD¹, I.E. ROGOZHINA¹, U.V. STOLYAROVA¹, A.V. DANILINA², I.N. SKUPOVA¹, O.V. TIKHANINA¹

¹Saratov State Medical University named after V.I. Razumovsky, 112 Bolshaya Kazachya St., Saratov, Russian Federation 410012

²Central Scientific-Research Institute of Epidemiology of Rospotrebnadzor, 3a Novogireevskaya St., Moscow, Russian Federation 111123

Neyfeld I.V. — Candidate of Medical Science, associate professor at the Department of Obstetrics and Gynecology of Advanced Training Faculty and Professional Retraining of Specialists, тел. (8452) 51-67-98, e-mail: kafed-ra@yandex.ru¹

Rogozhina I.E. — D. med. Sc., Assistant Professor, Head of Department of Obstetrics and Gynecology of Advanced Training Faculty and Professional Retraining of Specialists, tel. (8452) 51-67-98, e-mail: itg.r@yandex.ru¹

Stolyarova U.V. — Candidate of Medical Science, Assistant at the Department of Obstetrics and Gynecology of Advanced Training Faculty and Professional Retraining of Specialists, tel. (8452) 51-67-98, e-mail: kafed-ra@yandex.ru¹

Danilina A.V. — senior research associate of the Laboratory of Immunology and Biotechnology, tel. (495) 672-11-29, e-mail: kafed-ra@yandex.ru²

Skupova I.N. — Assistant at the Department of Obstetrics and Gynecology of Advanced Training Faculty and Professional Retraining of Specialists, tel. (8452) 51-67-98, e-mail: kafed-ra@yandex.ru¹

Tikhanina O.V. — Student of the 6th year, tel. (8452) 51-67-98, e-mail: kafed-ra@yandex.ru¹

Were studied the mechanisms of immunological disorders in 37 women with ovarian cancer in the process of cycle chemotherapy (CT). It is shown that the inclusion of СT imunofan (treatment group) has improved the immunological reactivity, contributed to increasing the total volume of specific therapy. Completeness of cycle chemotherapy in the study group was 94.7%, in the comparison group — 72.2%.

Keywords: ovarian cancer, chemotherapy, immunomodulating therapy.

REFERENCES

1. Baryshnikov A.Yu. The relationship of a tumor and immune system. Prakticheskaya onkologiya, 2003, vol. 4, no. 3 (15), pp. 127-130. (in Russ.).

2. Radke J., Schmidt D., Bohme M., Morenz J., Weise W. Leukocytes and lymphocyte subsets in peripheral blood and malignant ascites of patients with ovarian cancer. Geburtshilfe und Frauenheilkunde, 1994, vol. 54, no. 12, pp. 675-678. (in German).

3. Kadagidze Z.G. Modern possibilities of clinical immunology in oncology. Vestnik Rossiyskoy akademii meditsinskikh nauk [Bulletin of the Russian Academy of Medical Sciences], 2002, no. 1, pp. 4-8. (in Russ.).

4. Gorbunova V.A. Modern possibilities of drug therapy for ovarian cancer. Sovremennye eksperimental’nye i klinicheskie podkhody k diagnostike i ratsional’nomu lecheniyu raka yaichnikov [Modern experimental and clinical approaches to the diagnosis and rational treatment ofovariancancer]. Moscow, 2001, pp. 66-67.

5. Mancini G., Carbonara A., Heremans J.F. Immunochemical quantitation of antitgens by single radial immunodiffusion. Immunochemistry, 1965, vol. 2, no. 3, pp. 235-254.